Ali Kaan Guren

28PUBLICATIONS
199CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical infection agents (incl. prions)Medical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Sep 15, 2026
Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.

|Aug 27, 2026
Stage-Specific Prognostic Impact of Longitudinal Body Composition Changes in Patients with Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX: A Dual-Cohort Study.

|Aug 26, 2026
Revisiting Platinum Sensitivity in Relapsed Small-Cell Lung Cancer: Outcomes of Platinum-Containing Doublet Chemotherapy in the 3-6 Month Relapse Window.

|Jul 15, 2026
Long-Term Outcomes and Conditional Recurrence-Free Survival in Stage II Colon Cancer: The Impact of Surveillance and Recurrence Detection Strategies.

|Jun 25, 2026
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

|Jun 19, 2026
Efficacy and safety of sacituzumab govitecan in hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.

Pageof 5

Frequent Collaborators

12 joint publications

Murat Sarı

11 joint publications

İbrahim Vedat Bayoğu

11 joint publications

Mustafa Alperen Tunç

10 joint publications

Nargiz Majidova